Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.5.4.4 (
adenosine deaminase
)
5,136
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
2'-Deoxycoformycin (DCF) is a potent inhibitor of
adenosine deaminase
(
ADA
) and a potential antineoplastic and immunosuppressive agent. In this study the kinetics of
ADA
expression was assessed by immunomorphologic and enzymatic methods in tissues of
ACI
rats given injections of DCF. The rats received a daily ip injection of 10 mg DCF/kg for 3 consecutive days. This treatment destroyed cortical thymocytes, whereas lymphocytes of the thymic medulla were mainly preserved. In control phosphate-buffered saline-injected rats, cortical thymocytes were not affected morphologically and displayed strong
ADA
staining. It was found unexpectedly that injections of DCF produced activation and, possibly, differentiation of B-cells in the mesenteric lymph nodes and spleen. These activated B-lymphocytes and plasma cells stained strongly for
ADA
. Transient changes in patterns of
ADA
expression were also observed in endothelial cells of blood vessels and liver Kupffer's cells, but these changes were not accompanied by degeneration of the cells. The treatment with DCF did not result in any permanent abnormalities in the rat tissues.
...
PMID:Morphologic changes and immunohistochemical localization of adenosine deaminase in tissues of rats given injections of 2'-deoxycoformycin. 635 8
In
ACI
/N rats pretreated with cyclophosphamide (CY) growth of the bladder cancer, BC-47, and
adenosine deaminase
(
ADA
) and purine nucleoside phosphorylase (PNP) activities in lymphocytes were investigated to clarify the possible antitumor effect via the immune system of the chemotherapeutic agent. A single dose of 50 mg/kg of CY with the tumor implantation 3 days later gave rise to tumor regression following temporary progression around day 15 and significant increase of peripheral lymphocytes with higher PNP activity on days 7 to 10 of the tumor implantation. In the thymus such lymphocytes increased 3 days earlier. The antitumor effect was not demonstrated in athymic nude mice. In the light of the results and elimination of suppressor T precursors by CY, it was postulated that T lymphocytes with higher PNP activity act as effector cells in the antitumor immunity whereas suppressor T precursors belong to the cell population with lower PNP activity.
...
PMID:Host-mediated inhibition of rat bladder cancer growth by cyclophosphamide and purine salvage pathway-related enzyme activity of lymphocytes. 644 29
